Evaluation of the efficacy and safety of tegileridine at different doses in patients with postoperative pain: a meta-analysis of randomized controlled trials

Why clinicians should know about it

• Picked for Pulmonary and Respiratory Medicine (top studies of the week, 26 July 2026).

Abstract

OBJECTIVE: This study aims to comprehensively evaluate the efficacy and safety of tegileridine at different doses in patients with postoperative acute pain through a meta-analysis. METHODS: A systematic literature search was conducted across six databases from their inception to 24 March 2026 to identify all randomized controlled trials (RCTs) involving tegileridine for the treatment of postoperative acute pain. Meta-analyses were performed using RevMan 5.4 software. RESULTS: A total of four cohorts from three RCTs involving 1,011 patients were included. Compared with placebo, tegileridine significantly reduced rSPID24 and rSPID12, demonstrating superior analgesic efficacy. Compared with morphine, there was no significant difference at rSPID12; however, tegileridine exhibited significantly weaker efficacy than morphine at rSPID24. Safety analyses revealed that although the total adverse events with tegileridine were higher than with placebo, it remained comparable to that of morphine. The incidence of nausea and vomiting with tegileridine was similar to that with placebo and significantly lower than that with morphine. No significant difference was observed in the incidence of respiratory depression between tegileridine and morphine. CONCLUSION: This meta-analysis demonstrates that the efficacy of tegileridine was significantly superior to that of placebo, and it had a more favorable safety profile than morphine regarding nausea and vomiting, suggesting its potential as a viable alternative for postoperative acute pain. SYSTEMATIC REVIEW REGISTRATION: [https://www.crd.york.ac.uk/prospero/view/CRD420261364062/1/0], PROSPERO CRD420261364062.

Abstract as published, via PubMed.